BMY — Bristol-Myers Squibb Company

Summary of Bristol-Myers Squibb Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Approximately $11.5 billion, up 1% year-over-year.
• Growth Portfolio Sales: Increased by 9% to $6.2 billion, driven by products like Reblozyl, Breyanzi, and Opdualag.
• Eliquis Revenue: Approximately $4.1 billion, a 13% increase, benefiting from a U.S. price reduction.
• Opdivo Revenue: Decreased by 8% to $2.1 billion, primarily due to inventory drawdowns in the U.S.
• Gross Margin: Declined by 280 basis points to 70.3%, attributed to product mix.
• Diluted EPS: Reported at $1.58, including a net charge of $0.03 related to in-process R&D.
• Operating Cash Flow: Approximately $1.1 billion generated in the quarter.

2. Strategic Updates and Business Highlights

• R&D Focus: Continued emphasis on life-threatening diseases with a diversified pipeline, including advancements in CELMoDs (iberdomide and mezignomide) and ADCs.
• Regulatory Milestones: FDA accepted the iberdomide filing with breakthrough therapy designation; positive interim data reported for mezignomide and other products.
• Life Cycle Management: New approvals for SOTYKTU and Opdivo in additional indications.
• Cost Savings Initiative: On track to deliver $2 billion in savings by the end of 2027, allowing for reinvestment in growth opportunities.

3. Forward Guidance and Outlook

• 2026 Financial Guidance: Reaffirmed, with expectations to track towards the upper end of established revenue and EPS guidance.
• Pivotal Readouts: Anticipated late in 2026, including data for Milvexian and iberdomide, which are expected to enhance the long-term growth profile.
• Business Development: Continued focus on strategic acquisitions to enhance the portfolio, with flexibility to pursue opportunities that align with long-term goals.

4. Bad News, Challenges, or Points of Concern

• Opdivo Decline: The 8% revenue drop raises concerns about its market position, particularly with increasing competition.
• Gross Margin Pressure: The decline in gross margin indicates potential challenges in maintaining profitability amidst a changing product mix.
• Generic Competition: Continued impact from generic entries affecting legacy products, necessitating a robust strategy to mitigate revenue loss.
• Market Dynamics: Competitive pressures in the oncology space, particularly with new entrants and evolving treatment paradigms.

5. Notable Q&A Insights

• Clinical Readouts: Confidence expressed in upcoming pivotal trials for iberdomide and Milvexian, with a focus on their potential to reshape the company's growth trajectory.
• Business Development Strategy: The company remains open to strategic acquisitions, emphasizing the importance of enhancing both near-term and long-term growth.
• Cobenfy and CELMoDs: Positive feedback on the potential of Cobenfy in treating Alzheimer’s-related psychosis and the competitive positioning of CELMoDs in the multiple myeloma market.
• Market Opportunities: Discussion on the need for improved therapies in IPF and PPF, with Admilparant positioned as a potential first-line treatment due to its favorable efficacy and tolerability profile.

Overall, Bristol-Myers Squibb demonstrated solid performance in Q1 2026, with a focus on strategic growth initiatives and a diversified pipeline, while also facing challenges from competitive pressures and market dynamics.